Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Lymphoma | Research

A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma

Authors: Yifei Liu, Tingting Bian, Yanlin Zhang, Yuanyuan Zheng, Jianguo Zhang, Xiaoge Zhou, Jianlan Xie

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

To evaluate the clinical utility of LIM Domain Only 2 (LMO2) negative and CD38 positive in diagnosis of Burkitt lymphoma (BL).

Methods

LMO2 and CD38 expression determined by immunohistochemistry in 75 BL, 12 High-grade B-cell lymphoma, NOS (HGBL,NOS) and 3 Burkitt-like lymphomas with the 11q aberration.

Results

The sensitivity and specificity of LMO2 negative for detecting BL were 98.67 and 100%, respectively; those of CD38 positive were 98.67 and 66.67%, respectively. The sensitivity and specificity of a combination of both for detecting BL were 97.33 and 100%, respectively. In our study, the combined LMO2 negative and CD38 positive results had a higher area under the curve than either LMO2 negative or CD38 positive alone.

Conclusions

A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.
Literature
1.
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.PubMedCrossRef
2.
Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248–60.PubMedPubMedCentralCrossRef
3.
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431–42.PubMedCrossRef
4.
Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet. 2012;379(9822):1234–44.PubMedCrossRef
5.
Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361–4.PubMedCrossRef
6.
Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1333–43.PubMedCrossRef
7.
Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835–43.PubMedCrossRef
8.
Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20(40):5595–610.PubMedCrossRef
9.
10.
Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187–98.PubMedPubMedCentralCrossRef
11.
Ferreiro JF, Morscio J, Dierickx D, Marcelis L, Verhoef G, Vandenberghe P, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica. 2015;100(7):e275–9.PubMedPubMedCentralCrossRef
12.
Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, et al. LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia. 2009;11(7):712–9.PubMedPubMedCentralCrossRef
13.
Kim SH, Kim EJ, Hitomi M, Oh SY, Jin X, Jeon HM, et al. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells. Cell Death Differ. 2015;22(9):1517–25.PubMedPubMedCentralCrossRef
14.
Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636–42.PubMedPubMedCentralCrossRef
15.
van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
16.
Bras AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, Te Marvelde JG, van den Heuvel-Eibrink MM, et al. CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol. 2018;180(2):292–6.PubMedCrossRef
17.
van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95–112.PubMedPubMedCentralCrossRef
18.
de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg lymphoma biomarker consortium). J Clin Pathol. 2009;62(2):128–38.PubMedCrossRef
19.
Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98(10):1554–62.PubMedPubMedCentralCrossRef
20.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.PubMedCrossRef
21.
Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: Users' guides to the medical literature. JAMA. 2017;318(14):1377–84.PubMedCrossRef
22.
Haralambieva E, Schuuring E, Rosati S, van Noesel C, Jansen P, Appel I, et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer. 2004;40(1):10–8.PubMedCrossRef
23.
Pienkowska-Grela B, Rymkiewicz G, Grygalewicz B, Woroniecka R, Krawczyk P, Czyz-Domanska K, et al. Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. Med Oncol. 2011;28(4):1589–95.PubMedCrossRef
24.
Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, et al. LMO2-negative expression predicts the presence of MYC translocations in aggressive B-cell lymphomas. Am J Surg Pathol. 2017;41(7):877–86.PubMedCrossRef
25.
Agostinelli C, Paterson JC, Gupta R, Righi S, Sandri F, Piccaluga PP, et al. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. Histopathology. 2012;61(1):33–46.PubMedCrossRef
26.
Menter T, Gasser A, Juskevicius D, Dirnhofer S, Tzankov A. Diagnostic utility of the germinal center-associated markers GCET1, HGAL, and LMO2 in Hematolymphoid neoplasms. Appl Immunohistochem Mol Morphol. 2015;23(7):491–8.PubMedCrossRef
27.
Barth TF, Müller S, Pawlita M, Siebert R, Rother JU, Mechtersheimer G, et al. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. J Pathol. 2004;203(4):940–5.PubMedCrossRef
28.
Naresh KN, Ibrahim HA, Lazzi S, Rince P, Onorati M, Ambrosio MR, et al. Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries. Br J Haematol. 2011;154(6):770–6.PubMedCrossRef
29.
Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32(1):113–22.PubMedCrossRef
30.
Cogliatti SB, Novak U, Henz S, Schmid U, Möller P, Barth TF, et al. Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol. 2006;134(3):294–301.PubMedCrossRef
31.
Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Müller-Hermelink HK, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005;29(8):1086–94.PubMed
32.
McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, et al. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29(12):1652–60.PubMedCrossRef
33.
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63.PubMedCrossRef
34.
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7.PubMedCrossRef
35.
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9.PubMedPubMedCentralCrossRef
36.
Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612–9.PubMedCrossRef
37.
Tapia G, Lopez R, Muñoz-Mármol AM, Mate JL, Sanz C, Marginet R, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59(4):672–8.PubMedCrossRef
38.
Cook JR, Goldman B, Tubbs RR, Rimsza L, Leblanc M, Stiff P, et al. Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol. 2014;38(4):494–501.PubMedPubMedCentralCrossRef
39.
Lynnhtun K, Renthawa J, Varikatt W. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis. Pathology. 2014;46(3):211–5.PubMedCrossRef
40.
Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382–91.PubMedCrossRef
41.
Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294–303.PubMedCrossRef
Metadata
Title
A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma
Authors
Yifei Liu
Tingting Bian
Yanlin Zhang
Yuanyuan Zheng
Jianguo Zhang
Xiaoge Zhou
Jianlan Xie
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Lymphoma
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0876-3

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue

Research

Clinicopathological characteristics and molecular abnormalities of primary grade 2 neuroendocrine tumors of the cervix

Research

Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC)

Case Report

Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review

Research

Expression of GCRG213p, LINE-1 endonuclease variant, significantly different in gastric complete and incomplete intestinal metaplasia

Case Report

Mesonephric adenocarcinoma of the cervix: a case report with a three-year follow-up, lung metastases, and next-generation sequencing analysis

Case Report

Malakoplakia of the colon following renal transplantation in a 73 year old woman: report of a case presenting as intestinal perforation